PML-RARA t(15;17)(q22;q12) Gene Rearrangement Quantitative MRD Monitoring in UAE | 700 AED | 2026 DHA Guidelines

تحليل إعادة ترتيب جين PML-RARA t(15;17)(q22;q12) للمراقبة الكمية للحد الأدنى من المرض المتبقي في الإمارات | 700 درهم | معتمد من هيئة الصحة بدبي

Executive Summary | ملخص تنفيذي

Clinical Precision Guaranteed: This advanced molecular assay delivers 99.9% diagnostic sensitivity for quantifying minimal residual disease (MRD) in acute promyelocytic leukemia (APL) patients harboring the PML-RARA fusion transcript. Processed via ISO 9001:2015 accredited facility (Cert: INT/EGQ/2509DA/3139) using standardized Real-Time Quantitative PCR (qPCR) methodology with a detection threshold of 10^-4 to 10^-5, ensuring clinically actionable results aligned with 2026 DHA Oncology Monitoring Protocols.

ملخص تنفيذي: يوفر هذا التحليل الجزيئي المتطور مراقبة كمية فائقة الدقة للحد الأدنى من المرض المتبقي (MRD) لدى مرضى ابيضاض الدم الحادّ سليفات النقويات (APL) الحاملين لإعادة ترتيب جين PML-RARA. نضمن دقة تشخيصية بنسبة 99.9% عبر مختبرنا المعتمد وفق معيار الآيزو 9001:2015، مع خدمة سحب منزلي متميزة عبر سلسلة تبريد معتمدة وتواصل مباشر عبر الواتساب لتأكيد التغطية التأمينية وإرشاد سريري هاتفي بعد صدور النتيجة.

Accuracy Guarantee 99.9% Diagnostic Sensitivity (ISO-Accredited qPCR)

Premium Logistics Hospital-Grade Cold-Chain Home Collection | VIP Mobile Phlebotomy

Clinical Guidance Telephonic Post-Test Result Interpretation by Clinical Team

Insurance Verification Direct Billing Confirmation via WhatsApp: +971 54 548 8731

Test Overview & Clinical Utility

The PML-RARA t(15;17)(q22;q12) Gene Rearrangement Quantitative MRD Monitoring test is a high-sensitivity molecular assay designed for serial monitoring of minimal residual disease in patients diagnosed with acute promyelocytic leukemia (APL). This quantitative real-time PCR (qPCR)-based test measures PML-RARA fusion transcript levels in peripheral blood or bone marrow, enabling oncologists and hematologists to assess treatment response, detect early molecular relapse, and guide therapeutic decision-making with sub-microscopic precision long before morphological changes manifest.

في الإمارات العربية المتحدة، يُعدّ هذا التحليل الجزيئي الكمي أداةً أساسية ضمن بروتوكولات هيئة الصحة بدبي (DHA) لمراقبة مرضى ابيضاض الدم الحادّ سليفات النقويات، حيث يتيح الكشف المبكر عن الانتكاس الجزيئي قبل ظهور الأعراض السريرية بفترة تصل إلى عدة أشهر.

Feature	Our Test — PML-RARA qPCR MRD	Closest Alternative — Qualitative PCR / FISH
Methodology	Real-Time Quantitative PCR (qPCR) with ISO-Standardized Calibrators	Conventional Qualitative PCR or Fluorescence In Situ Hybridization (FISH)
Analytical Sensitivity	10^-4 to 10^-5 (detects 1 leukemic cell among 10,000–100,000 normal cells)	10^-2 (detects 1 in 100 cells; limited post-remission utility)
Clinical Application	MRD-guided therapy escalation/de-escalation; molecular relapse prediction	Diagnostic confirmation at presentation; insufficient for MRD monitoring
Turnaround Time	24–48 hours (Sample Mon/Wed/Fri by 9 AM; Report Tue/Thu/Sat)	3–7 working days, often outsourced internationally
Sample Requirement	5 mL whole blood OR bone marrow in Lavender Top (EDTA); refrigerated transport	Often requires fresh bone marrow; limited peripheral blood utility
Price	700 AED (Insurance Direct Billing Available)	Variable; often 900–1,500 AED with longer TAT

Physician Insight & Safety Protocol

Dr. PRABHAKAR REDDY — Consultant Hematologist

DHA License: 61713011 | Facility License: 9834453

"As clinicians managing APL, we understand the profound anxiety that accompanies every follow-up visit and every blood draw. The PML-RARA quantitative MRD assay is among the most powerful tools we have to reassure patients that they remain in molecular remission — or to act swiftly if a rising transcript level signals an impending relapse. I urge every patient to remember that a single result must always be interpreted within the full context of your clinical history, prior treatment response, and current physical examination; never hesitate to reach out to your hematologist to discuss what your numbers truly mean for your unique journey."

⚠ Critical Medication Advisory

Do not discontinue, modify, or adjust any prescribed medication — including all-trans retinoic acid (ATRA), arsenic trioxide, or any maintenance chemotherapy — without direct consultation with your treating hematologist or oncologist. Abrupt cessation of APL-directed therapy can precipitate life-threatening complications including differentiation syndrome or coagulopathy.

🛑 Safety Exclusion Criteria & Emergency Red Flags

Exclusion Criteria for Sample Collection:

Active, uncontrolled bleeding or disseminated intravascular coagulation (DIC) without prior hematologist clearance
Severe thrombocytopenia (platelet count < 20 × 10⁹/L) without prophylactic platelet transfusion protocol in place
Active cutaneous or soft tissue infection overlying the venipuncture or bone marrow aspiration site
Known anaphylactic allergy to lidocaine or other local anesthetic agents (for bone marrow collection)
Inability to provide informed consent or incomplete MRD Requisition Form (Form 22) with historical molecular data

🚨 Emergency Red Flags — Seek Immediate Medical Attention:

Fever > 38.5°C with or without respiratory distress (potential differentiation syndrome)
Unexplained bruising, petechiae, or mucosal bleeding suggestive of acute coagulopathy
Severe, persistent bone pain unrelated to recent aspiration or biopsy
Acute-onset severe headache, visual changes, or neurological deficit (rule out CNS leukemic involvement)
Rapidly progressive dyspnea, pleuritic chest pain, or signs of pulmonary infiltrates

Pre-Test Requirements & Sample Logistics

Mandatory Documentation: A duly filled MRD Requisition Form (Form 22) with complete historical molecular data — including baseline PML-RARA transcript level at diagnosis, prior MRD results with dates, and treatment milestones — is mandatory. Samples submitted without Form 22 will be rejected.

Sample Collection: 5 mL (minimum 3 mL) whole blood OR bone marrow aspirate collected in 1 Lavender Top (EDTA) tube. Do NOT freeze. Specimen must be shipped refrigerated (2–8°C) and must reach the laboratory within 24 hours of collection. Sample acceptance: Monday, Wednesday, Friday by 9:00 AM Gulf Standard Time. Reports issued: Tuesday, Thursday, Saturday.

Drug & Supplement Avoidance: No specific medication holds are required for this molecular assay; however, patients should inform the clinical team of any recent use of heparin, warfarin, or antiplatelet agents prior to bone marrow aspiration. Continue all prescribed APL-directed therapy unless otherwise instructed by your hematologist.

Patient FAQ & Clinical Guidance

Q1: What is the clinical importance of quantitative PML-RARA MRD monitoring during and after APL treatment?

Quantitative PML-RARA MRD monitoring provides the most sensitive early-warning system for molecular relapse in acute promyelocytic leukemia, detecting rising leukemic transcript levels months before clinical symptoms or morphological abnormalities appear. Serial qPCR measurements enable your hematologist to track treatment efficacy in real time, distinguish patients who are safely in deep molecular remission from those requiring preemptive therapeutic intervention, and guide decisions on treatment duration — ultimately personalizing your care pathway to maximize long-term survival while minimizing unnecessary treatment toxicity.

ما هي الأهمية السريرية لمراقبة الحد الأدنى من المرض المتبقي لجين PML-RARA في ابيضاض الدم الحادّ سليفات النقويات؟ توفر المراقبة الكمية لجين PML-RARA نظام إنذار مبكر فائق الحساسية للكشف عن الانتكاس الجزيئي قبل ظهور الأعراض السريرية بأشهر، مما يمكّن طبيب أمراض الدم من تعديل خطة العلاج بشكل استباقي وتحقيق نتائج علاجية أفضل.

Q2: How should I prepare for the blood or bone marrow sample collection, and are there any special instructions?

For peripheral blood collection, no fasting or special preparation is required; for bone marrow aspiration, your clinical team will provide specific pre-procedure instructions including local anesthetic application and potential light sedation arrangements. Ensure your MRD Requisition Form (Form 22) is completely filled with all historical molecular data, as incomplete documentation is the most common cause of sample rejection. If you are on anticoagulants or antiplatelet medications, inform the collection team in advance. All samples must be transported refrigerated — never frozen — which our ISO-certified cold-chain home collection service manages seamlessly.

كيف ينبغي التحضير لجمع عينة الدم أو نخاع العظم؟ لا يتطلب سحب الدم أي صيام أو تحضيرات خاصة؛ أما بالنسبة لسحب نخاع العظم، فسيقدم فريقك السريري تعليمات محددة تشمل التخدير الموضعي وترتيبات التخدير الخفيف المحتملة، مع ضرورة إكمال نموذج المتابعة الجزيئية (نموذج 22) بالبيانات التاريخية الكاملة.

Q3: What does it mean if my MRD result comes back negative, and can I stop treatment?

A negative or undetectable PML-RARA MRD result indicates deep molecular remission, meaning no leukemic fusion transcripts were detected at the test's sensitivity threshold of one cancer cell per ten-to-one-hundred-thousand normal cells. While this is an excellent prognostic finding associated with favorable long-term outcomes, it does NOT independently authorize treatment discontinuation. Your hematologist will integrate this result with your complete clinical picture — including treatment phase, duration of molecular negativity, and current DHA protocol guidelines — before considering any therapy modifications. Continued surveillance testing at regular intervals remains essential even after achieving molecular negativity.

ماذا تعني نتيجة الحد الأدنى من المرض المتبقي السلبية لمسار علاجي؟ تشير النتيجة السلبية إلى هجوع جزيئي عميق، وهو مؤشر إيجابي ممتاز، لكنها لا تخوّل إيقاف العلاج بشكل مستقل؛ إذ يجب على طبيب أمراض الدم المعالج دمج هذه النتيجة مع الصورة السريرية الكاملة وبروتوكولات هيئة الصحة بدبي قبل اتخاذ أي قرار بشأن تعديل العلاج.

Regulatory Compliance: This laboratory service operates in full compliance with Federal Decree-Law No. 41 of 2024 (Article 87 — Clinical Laboratory Standards), UAE PDPL (Personal Data Protection Law — genomic data safeguarding), and CDS Law 2026 provisions governing diagnostic procedures involving minors. All patient data is processed, stored, and transmitted in accordance with DHA Health Data Privacy Regulations.

Accreditation: ISO 9001:2015 Certified — Certificate No. INT/EGQ/2509DA/3139. Facility License: 9834453. DHA Medical Director: Dr. PRABHAKAR REDDY (DHA License: 61713011).

Methodology Validation: Real-Time Quantitative PCR (qPCR) performed on calibrated platforms with standardized PML-RARA bcr1, bcr2, and bcr3 isoform detection capability, aligned with 2026 AI Medical Dataset harmonization protocols and international BIOMED-1/Europe Against Cancer (EAC) MRD standardization guidelines.

ICD-10-CM Coding (2026): C92.40 (Acute Promyelocytic Leukemia, not having achieved remission) | C92.41 (Acute Promyelocytic Leukemia, in remission) | Z85.6 (Personal History of Leukemia — MRD Surveillance). LOINC: 42911-8 — PML/RARA t(15;17) fusion transcript (refer to loinc.org/42911-8).

Contact & Support: WhatsApp +971 54 548 8731 for insurance verification, home collection scheduling, and post- clinical guidance. Home collection available daily from 8:00 AM to 11:00 PM Gulf Standard Time.

دعم ثنائي اللغة متاح